

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/696,268		
		Filing Date	October 29, 2003		
		First Named Inventor	Sang Nyun KIM et al.		
		Group Art Unit	1646		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	4084-032129

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T²
JR		MAURER et al., "Hair Growth Modulation by Topical Immunophilin Ligands," <u>American Journal of Pathology</u> , 1997, pp. 1433-41, Vol. 150, No. 4.	
JR		EBERLE et al., "Cyclosporin A: Regioselective Ring Opening and Fragmentation Reactions via Thioamides. A Route to Semisynthetic Cyclosporins," <u>J. Org. Chem.</u> , 1994, pp. 7249-7258, Vol. 59, No. 24.	
JR		LUTZ, "Effects of Cyclosporin A on Hair," <u>Skin Pharmacol.</u> , 1994, pp. 101-4, Vol. 7.	
JR		EBERLE et al., "Preparation of [D-Cysteine]-cyclosporin via Intramolecular Sulfur Transfer Reaction," <u>J. Org. Chem.</u> , 1993, pp. 673-677, Vol. 58, No. 3.	
JR		SEEBACH et al., "Thiocyclosporins: Preparation, Solution and Crystal Structure, and Immunosuppressive Activity," <u>Helv. Chim. Acta</u> , 1991, pp. 1953-1990, Vol. 74.	
JR		GILHAR et al., "Topical cyclosporine in male pattern alopecia," <u>J. Am. Acad. Dermatol.</u> , 1990, pp. 251-3, Vol. 22, No. 2.	
JR		GUPTA et al., "Oral cyclosporine for the treatment of alopecia areata," <u>J. Am. Acad. Dermatol.</u> , 1990, pp. 242-50, Vol. 22, No. 2.	
JR		VON TRABER et al., "Novel Cyclosporins from <i>Tolypocladium inflatum</i> . The Cyclosporins K-Z," <u>Helv. Chim. Acta</u> , 1987, pp. 13-36, Vol. 70.	
JR		YAMAMOTO et al., "Hair Growth-Stimulating Effects of Cyclosporin A and FK506, Potent Immunosuppressants," <u>Journal of Dermatological Science</u> 7 (Suppl.), 1994, pp. 547-554.	
JR		BOREL et al., "In Vivo Pharmacological Effects of Cyclosporin and Some Analogues," <u>Advances in Pharmacology</u> , Vol. 35, pp. 145-246, 1996, Exhibit A. Pages 115, 178, 179.	
JR		PAUS et al., "Hair Growth Control by Immunosuppression," <u>Arch. Dermatol. Res.</u> (1996) 288:408-410 (see in particular Table 1) (Exhibit B)	

Examiner Signature	Jeffrey E. Russell	Date Considered	December 7, 2007
--------------------	--------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. ‡See attached Kinds of U.S. Patent Documents. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ††Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.